Timeline
Oxford BioDynamics
Oxford BioDynamics lands first paid deal for Orion platform
Oxford BioDynamics shows revenue growth, new CEO starts, and lands a new US partnership
Oxford BioDynamics signs contract sales partnership to accelerate US prostate cancer test uptake
More in Medtech & Diagnostics
GENinCode genetic test cuts cardiac risk in Catalonia pilot
A real-world pilot by Catalonia's health service found GENinCode's CARDIO inCode-Score reclassified risk in over 40% of moderate-risk patients and drove measurable improvements in cholesterol and smoking cessation.